Literature DB >> 31428846

Closing the 'phenotype gap' in precision medicine: improving what we measure to understand complex disease mechanisms.

Calum A MacRae1.   

Abstract

The central concept underlying precision medicine is a mechanistic understanding of each disease and its response to therapy sufficient to direct a specific intervention. To execute on this vision requires parsing incompletely defined disease syndromes into discrete mechanistic subsets and developing interventions to precisely address each of these etiologically distinct entities. This will require substantial adjustment of traditional paradigms which have tended to aggregate high-level phenotypes with very different etiologies. In the current environment, where diagnoses are not mechanistic, drug development has become so expensive that it is now impractical to imagine the cost-effective creation of new interventions for many prevalent chronic conditions. The vision of precision medicine also argues for a much more seamless integration of research and development with clinical care, where shared taxonomies will enable every clinical interaction to inform our collective understanding of disease mechanisms and drug responses. Ideally, this would be executed in ways that drive real-time and real-world discovery, innovation, translation, and implementation. Only in oncology, where at least some of the biology is accessible through surgical excision of the diseased tissue or liquid biopsy, has "co-clinical" modeling proven feasible. In most common germline disorders, while genetics often reveal the causal mutations, there still remain substantial barriers to efficient disease modeling. Aggregation of similar disorders under single diagnostic labels has directly contributed to the paucity of etiologic and mechanistic understanding by directly reducing the resolution of any subsequent studies. Existing clinical phenotypes are typically anatomic, physiologic, or histologic, and result in a substantial mismatch in information content between the phenomes in humans or in animal 'models' and the variation in the genome. This lack of one-to-one mapping of discrete mechanisms between disease and animal models causes a failure of translation and is one form of 'phenotype gap.' In this review, we will focus on the origins of the phenotyping deficit and approaches that may be considered to bridge the gap, creating shared taxonomies between human diseases and relevant models, using cardiovascular examples.

Entities:  

Mesh:

Year:  2019        PMID: 31428846     DOI: 10.1007/s00335-019-09810-7

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  92 in total

1.  Emergence of scaling in random networks

Authors: 
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

Review 2.  The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.

Authors:  J G Seidman; C Seidman
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 3.  Molecular and cellular mechanisms of cardiac arrhythmias.

Authors:  M T Keating; M C Sanguinetti
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

4.  The large-scale organization of metabolic networks.

Authors:  H Jeong; B Tombor; R Albert; Z N Oltvai; A L Barabási
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

5.  Quantitative neural indicators of liability to schizophrenia: implications for molecular genetic studies.

Authors:  T D Cannon; T L Gasperoni; T G van Erp; I M Rosso
Journal:  Am J Med Genet       Date:  2001-01-08

6.  William Johannsen and the genotype concept.

Authors:  F B Churchill
Journal:  J Hist Biol       Date:  1974       Impact factor: 1.326

7.  Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.

Authors:  D L Garver; J A Holcomb; J D Christensen
Journal:  J Clin Psychiatry       Date:  2000-12       Impact factor: 4.384

8.  High-resolution mapping of quantitative trait loci in outbred mice.

Authors:  C J Talbot; A Nicod; S S Cherny; D W Fulker; A C Collins; J Flint
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

9.  A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations.

Authors:  L M Raamsdonk; B Teusink; D Broadhurst; N Zhang; A Hayes; M C Walsh; J A Berden; K M Brindle; D B Kell; J J Rowland; H V Westerhoff; K van Dam; S G Oliver
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

Review 10.  Searching for genetic determinants in the new millennium.

Authors:  N J Risch
Journal:  Nature       Date:  2000-06-15       Impact factor: 49.962

View more
  3 in total

Review 1.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

2.  Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation.

Authors:  Merry L Lindsey; Kristine Y Deleon-Pennell; Amy D Bradshaw; R Amanda C Larue; Daniel R Anderson; Geoffrey M Thiele; Catalin F Baicu; Jeffrey A Jones; Donald R Menick; Michael R Zile; Francis G Spinale
Journal:  J Card Fail       Date:  2020-05-21       Impact factor: 6.592

3.  Plasmodium knowlesi - Clinical Isolate Genome Sequencing to Inform Translational Same-Species Model System for Severe Malaria.

Authors:  Damilola R Oresegun; Cyrus Daneshvar; Janet Cox-Singh
Journal:  Front Cell Infect Microbiol       Date:  2021-03-02       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.